Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ1,03
KB-0,31
PKN121,8121,85-6,31
Msft77,5877,59-0,01
IBM159,83159,850,19
DCX68,6668,68-0,94
PFE36,0736,080,68
19.10.2017 16:30:58
Indexy online
AD Index online
select
AD Index online
 

  • 19.10.2017 16:28:36
Concert Pharm (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
13,70 -1,86 -0,26 26 252
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.10.2017
Popis společnosti
Obecné informace
Název společnostiConcert Pharmaceuticals Inc
TickerCNCE
Kmenové akcie:Ordinary Shares
RICCNCE.O
ISINUS2060221056
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.6.2017
Počet zaměstnanců k 31.12.2016 69
Akcie v oběhu k 4.8.2017 22 687 187
Počet akcionářů k 31.12.2016 22
MěnaUSD
Kontaktní informace
Ulice99 Hayden Ave Ste 500
MěstoLEXINGTON
PSČ02421-7966
ZeměUnited States
Kontatní osobaJustine Koenigsberg
Funkce kontaktní osobyVice President - Corporate Communications
Telefon17 818 600 045
Fax13026365454
Kontatní telefon17 816 745 284

Business Summary: Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.
Financial Summary: BRIEF: For the six months ended 30 June 2017, Concert Pharmaceuticals Inc revenues decreased 72% to $35K. Net loss decreased 4% to $26.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research & Development exp decrease of 26% to $14.1M (expense), Investment Income increase of 29% to $292K (income).
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research - NEC
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSPharmaceutical Preparation Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 19.10.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Co-FounderRichard Aldrich62
President, Chief Executive Officer, Co-Founder, DirectorRoger Tung56
Principal Financial Officer, Principal Accounting OfficerRyan Lynch-15.6.2017
Chief Operating OfficerNancy Stuart55
Senior Vice President and General CounselRobert Silverman62
Senior Vice President, chief development officerJames Cassella,-
Vice President - Regulatory AffairsChristine Boisclair-6.9.20166.9.2016
Vice President - Commercial and Product StrategyScott Weintraub-6.9.20166.9.2016